SG11202113057XA - Ppr protein causing less aggregation and use of the same - Google Patents

Ppr protein causing less aggregation and use of the same

Info

Publication number
SG11202113057XA
SG11202113057XA SG11202113057XA SG11202113057XA SG11202113057XA SG 11202113057X A SG11202113057X A SG 11202113057XA SG 11202113057X A SG11202113057X A SG 11202113057XA SG 11202113057X A SG11202113057X A SG 11202113057XA SG 11202113057X A SG11202113057X A SG 11202113057XA
Authority
SG
Singapore
Prior art keywords
same
causing less
less aggregation
ppr protein
protein causing
Prior art date
Application number
SG11202113057XA
Other languages
English (en)
Inventor
Yusuke Yagi
Takayoshi Imai
Takayuki Tamai
Takahiro Nakamura
Takamasa TERAMOTO
Original Assignee
Editforce Inc
Univ Kyushu Nat Univ Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Editforce Inc, Univ Kyushu Nat Univ Corp filed Critical Editforce Inc
Publication of SG11202113057XA publication Critical patent/SG11202113057XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Environmental Sciences (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202113057XA 2019-05-29 2020-05-29 Ppr protein causing less aggregation and use of the same SG11202113057XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019100553 2019-05-29
PCT/JP2020/021473 WO2020241877A1 (ja) 2019-05-29 2020-05-29 凝集の少ないpprタンパク質及びその利用

Publications (1)

Publication Number Publication Date
SG11202113057XA true SG11202113057XA (en) 2021-12-30

Family

ID=73552159

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202113057XA SG11202113057XA (en) 2019-05-29 2020-05-29 Ppr protein causing less aggregation and use of the same

Country Status (10)

Country Link
US (1) US12559528B2 (cg-RX-API-DMAC7.html)
EP (1) EP3977849A4 (cg-RX-API-DMAC7.html)
JP (4) JP7308468B2 (cg-RX-API-DMAC7.html)
KR (1) KR102898966B1 (cg-RX-API-DMAC7.html)
CN (1) CN113966340A (cg-RX-API-DMAC7.html)
AU (2) AU2020283367B2 (cg-RX-API-DMAC7.html)
CA (1) CA3142303A1 (cg-RX-API-DMAC7.html)
IL (2) IL312349B2 (cg-RX-API-DMAC7.html)
SG (1) SG11202113057XA (cg-RX-API-DMAC7.html)
WO (1) WO2020241877A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114729017A (zh) * 2019-05-29 2022-07-08 日商基因编辑力股份有限公司 Ppr蛋白的有效制作方法及其应用
JP7125727B1 (ja) 2021-09-07 2022-08-25 国立大学法人千葉大学 核酸配列改変用組成物および核酸配列の標的部位を改変する方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006188507A (ja) * 2004-12-10 2006-07-20 Tokyo Univ Of Agriculture & Technology 蛋白質の溶解度向上方法
ES2751126T3 (es) * 2011-10-21 2020-03-30 Univ Kyushu Nat Univ Corp Método de diseño para proteína de unión a ARN usando motivo de PPR, y uso del mismo
KR20160007541A (ko) * 2013-04-22 2016-01-20 고쿠리쓰다이가쿠호진 규슈다이가쿠 피피알 모티프를 이용한 디앤에이 결합성 단백질 및 그의 이용
WO2017209122A1 (ja) 2016-06-03 2017-12-07 国立大学法人九州大学 標的mRNAからのタンパク質発現量を向上させるための融合タンパク質
JPWO2018030488A1 (ja) * 2016-08-10 2019-06-13 富士フイルム和光純薬株式会社 Pprモチーフを利用したdna結合性タンパク質およびその利用
JP6918686B2 (ja) 2017-11-28 2021-08-11 東芝ライフスタイル株式会社 冷蔵庫
KR102568600B1 (ko) 2018-02-19 2023-08-23 삼성디스플레이 주식회사 표시 장치, 이를 포함하는 적층 기판, 및 표시 장치 제조방법
CN114729017A (zh) 2019-05-29 2022-07-08 日商基因编辑力股份有限公司 Ppr蛋白的有效制作方法及其应用

Also Published As

Publication number Publication date
US20220220166A1 (en) 2022-07-14
IL288417B1 (en) 2024-06-01
KR102898966B1 (ko) 2025-12-10
JP7308468B2 (ja) 2023-07-14
IL288417A (en) 2022-01-01
IL288417B2 (en) 2024-10-01
JP7526399B2 (ja) 2024-08-01
WO2020241877A1 (ja) 2020-12-03
AU2020283367A1 (en) 2022-01-06
JP7749763B2 (ja) 2025-10-06
JPWO2020241877A1 (cg-RX-API-DMAC7.html) 2020-12-03
AU2020283367B2 (en) 2025-04-10
JP7880589B2 (ja) 2026-06-26
JP2023036848A (ja) 2023-03-14
IL312349B2 (en) 2025-04-01
US12559528B2 (en) 2026-02-24
EP3977849A4 (en) 2023-06-28
JP2025181985A (ja) 2025-12-11
NZ783357A (en) 2025-06-27
BR112021023937A2 (pt) 2022-04-19
JP2024138381A (ja) 2024-10-08
IL312349B1 (en) 2024-12-01
KR20220023984A (ko) 2022-03-03
AU2025205185A1 (en) 2025-07-31
EP3977849A1 (en) 2022-04-06
IL312349A (en) 2024-06-01
CA3142303A1 (en) 2020-12-03
CN113966340A (zh) 2022-01-21

Similar Documents

Publication Publication Date Title
ZA202006066B (en) Anti-hla-g antibodies and use thereof
ZA202101250B (en) Novel crispr-associated protein and use thereof
EP3235830A4 (en) Interleukin 15 protein complex and use thereof
IL282423A (en) CAS9 protein is strange, and its use
IL282707A (en) Anti-tim-3 antibodies and their use
EP3802613A4 (en) DIMER AND ITS USE
IL287003A (en) Anti-integrin antibodies and their uses
SG11202111462VA (en) Asx-specific protein ligases and uses thereof
IL282708A (en) Anti-tim-3 antibodies and their use
SG11202104912SA (en) Fusion protein and use thereof
EP3831945A4 (en) PROTEIN HETERODIMER AND ITS USE
ZA202100092B (en) Modified cas9 protein and use thereof
GB202201001D0 (en) Polypeptide and use thereof
PL3757295T3 (pl) Pojemnik i jego zastosowanie
EP3882263A4 (en) GLUCAGON DERIVED PEPTIDE AND USE THEREOF
IL277007A (en) Therapeutic ANTI-SPLA2-GIB antibodies and their uses
GB201819200D0 (en) Polypeptide and uses thereof
IL300235A (en) Synthetic proteins and their therapeutic uses
IL288417A (en) ppr protein which causes less aggregation and use
IL292599A (en) tmem219 antibodies and medical uses thereof
IL290643A (en) Peptides for transport and methods of using them
GB201802122D0 (en) Product and use
SG11202102412UA (en) Semiconductor aqueous composition and use of the same
IL289843A (en) Antibodies against methylthionine and their uses
IL288828A (en) Binding factors - cd38 and their use